Published in Cancer on May 15, 2004
Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system. Cancer Res (2008) 1.13
Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol (2015) 1.05
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol (2013) 0.95
Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid (2010) 0.94
The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) (2014) 0.91
Management of elderly patients with gliomas. Oncologist (2014) 0.86
Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther (2011) 0.83
Treatment of malignant gliomas in elderly patients: a concise overview of the literature. Biomed Res Int (2014) 0.80
Outcomes in newly diagnosed elderly glioblastoma patients after concomitant temozolomide administration and hypofractionated radiotherapy. Cancers (Basel) (2013) 0.79
High-grade glioma in elderly patients: can the oncogeriatrician help? Clin Interv Aging (2013) 0.79
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Cancer (2004) 0.75
Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma. Contemp Oncol (Pozn) (2016) 0.75
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 9.09
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol (2009) 5.06
OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain (2007) 3.35
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Primary brain tumours in adults. Lancet (2003) 3.05
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol (2012) 2.01
Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A (2001) 2.00
Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci (2005) 1.89
Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83
Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol (2007) 1.76
Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis. Am J Hum Genet (2013) 1.70
Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol (2004) 1.65
Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. Transplantation (2003) 1.65
Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res (2010) 1.59
Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases. Neurosurgery (2003) 1.58
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res (2012) 1.54
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol (2010) 1.48
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab (2010) 1.46
Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin Ther Targets (2010) 1.45
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol (2007) 1.42
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed (2011) 1.39
Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer (2006) 1.36
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol (2010) 1.36
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev (2006) 1.35
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol (2011) 1.34
Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro Oncol (2012) 1.32
Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain (2007) 1.29
A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol (2009) 1.28
Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'. Cancer Res (2000) 1.27
Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf (2009) 1.27
Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol (2002) 1.26
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol (2010) 1.25
Stereoelectroencephalography in presurgical assessment of MRI-negative epilepsy. Brain (2007) 1.24
Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res (2011) 1.24
Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol (2013) 1.22
Constitutive activation of the calcium sensor STIM1 causes tubular-aggregate myopathy. Am J Hum Genet (2013) 1.20
French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol (2007) 1.20
Percutaneous kyphoplasty and pedicle screw fixation for the management of thoraco-lumbar burst fractures. Eur Spine J (2010) 1.17
Cobblestone lissencephaly: neuropathological subtypes and correlations with genes of dystroglycanopathies. Brain (2012) 1.17
The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling. Genes Dev (2012) 1.16
Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat (2005) 1.15
Brainstem metastases: management using gamma knife radiosurgery. Neurosurgery (2006) 1.15
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol (2013) 1.15
Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer (2007) 1.14
Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab (2009) 1.14
Microtubules in apoptosis induction: are they necessary? Curr Cancer Drug Targets (2007) 1.14
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol (2001) 1.13
Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer (2008) 1.12
Metagenomic analysis of brain abscesses identifies specific bacterial associations. Clin Infect Dis (2011) 1.11
Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat (2009) 1.11
Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer (2007) 1.09
Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. J Neurosurg (2003) 1.09
A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer (2007) 1.08
Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) (2012) 1.08
Deciphering the 8q24.21 association for glioma. Hum Mol Genet (2013) 1.08
Striking phenotypic variability in two familial cases of myosin storage myopathy with a MYH7 Leu1793pro mutation. Neuromuscul Disord (2009) 1.07
The usefulness of MR imaging in the diagnosis of dysembryoplastic neuroepithelial tumor in children: a study of 14 cases. AJNR Am J Neuroradiol (2003) 1.07
Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol (2008) 1.07
French research infrastructures to develop and validate glioma biomarkers. Neurosurgery (2014) 1.07
Mutations in CNTNAP1 and ADCY6 are responsible for severe arthrogryposis multiplex congenita with axoglial defects. Hum Mol Genet (2013) 1.06
Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat (2005) 1.06
Local and remote epileptogenicity in focal cortical dysplasias and neurodevelopmental tumours. Brain (2009) 1.06
Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain (2012) 1.06
Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? J Neurooncol (2010) 1.05
Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol (2008) 1.05
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol (2007) 1.04
Microtubule targeting agents: from biophysics to proteomics. Cell Mol Life Sci (2010) 1.04
Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol (2013) 1.04
Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis. Cancer (2009) 1.03
Massive inflammatory syndrome and lymphocytic immunodeficiency in KARAP/DAP12-transgenic mice. Eur J Immunol (2002) 1.02
Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas. J Neurosurg (2002) 1.02
Microtubule-targeted agents: when mitochondria become essential to chemotherapy. Biochim Biophys Acta (2011) 1.02
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol (2011) 1.01
Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). Biochem Pharmacol (2000) 1.01
Electron microscopy in neuromuscular disorders. Ultrastruct Pathol (2005) 1.01
Association of telomerase gene hTERT polymorphism and malignant gliomas. J Neurooncol (2007) 1.01
Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol (2010) 1.01
Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases. Neurosurgery (2007) 1.00
Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg (2003) 0.99
High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol (2009) 0.99
Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J Neurosci Res (2001) 0.99
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol (2011) 0.99
Skeletal muscle biopsy analysis in reducing body myopathy and other FHL1-related disorders. J Neuropathol Exp Neurol (2013) 0.99
French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol (2011) 0.98
Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J (2009) 0.98